These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28080056)

  • 1. Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8.
    Callegari D; Lodola A; Pala D; Rivara S; Mor M; Rizzi A; Capelli AM
    J Chem Inf Model; 2017 Feb; 57(2):159-169. PubMed ID: 28080056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
    Cholko T; Chen W; Tang Z; Chang CA
    J Comput Aided Mol Des; 2018 Jun; 32(6):671-685. PubMed ID: 29737445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of CDK8/CycC Ligands with a New Virtual Screening Tool.
    Chen W; Ren X; Chang CA
    ChemMedChem; 2019 Jan; 14(1):107-118. PubMed ID: 30403831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-Atomic Molecular Dynamic Studies of Human and
    Xu W; Xie XJ; Faust AK; Liu M; Li X; Chen F; Naquin AA; Walton AC; Kishbaugh PW; Ji JY
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residence Time Prediction of Type 1 and 2 Kinase Inhibitors from Unbinding Simulations.
    Braka A; Garnier N; Bonnet P; Aci-Sèche S
    J Chem Inf Model; 2020 Jan; 60(1):342-348. PubMed ID: 31834793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
    Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
    Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using metadynamics and path collective variables to study ligand binding and induced conformational transitions.
    Bešker N; Gervasio FL
    Methods Mol Biol; 2012; 819():501-13. PubMed ID: 22183554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
    Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
    Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient States and Barriers from Molecular Simulations and the Milestoning Theory: Kinetics in Ligand-Protein Recognition and Compound Design.
    Tang Z; Chen SH; Chang CA
    J Chem Theory Comput; 2020 Mar; 16(3):1882-1895. PubMed ID: 32031801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations.
    Casasnovas R; Limongelli V; Tiwary P; Carloni P; Parrinello M
    J Am Chem Soc; 2017 Apr; 139(13):4780-4788. PubMed ID: 28290199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Drug-Target Residence Time in Kinases through Enhanced Sampling Simulations.
    Gobbo D; Piretti V; Di Martino RMC; Tripathi SK; Giabbai B; Storici P; Demitri N; Girotto S; Decherchi S; Cavalli A
    J Chem Theory Comput; 2019 Aug; 15(8):4646-4659. PubMed ID: 31246463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steered molecular dynamics simulations for studying protein-ligand interaction in cyclin-dependent kinase 5.
    Patel JS; Berteotti A; Ronsisvalle S; Rocchia W; Cavalli A
    J Chem Inf Model; 2014 Feb; 54(2):470-80. PubMed ID: 24437446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK8 kinase--An emerging target in targeted cancer therapy.
    Rzymski T; Mikula M; Wiklik K; Brzózka K
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1617-29. PubMed ID: 26006748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.
    Mollica L; Theret I; Antoine M; Perron-Sierra F; Charton Y; Fourquez JM; Wierzbicki M; Boutin JA; Ferry G; Decherchi S; Bottegoni G; Ducrot P; Cavalli A
    J Med Chem; 2016 Aug; 59(15):7167-76. PubMed ID: 27391254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Free-Energy Calculation and Machine Learning Methods for Understanding Ligand Unbinding Kinetics.
    Badaoui M; Buigues PJ; Berta D; Mandana GM; Gu H; Földes T; Dickson CJ; Hornak V; Kato M; Molteni C; Parsons S; Rosta E
    J Chem Theory Comput; 2022 Apr; 18(4):2543-2555. PubMed ID: 35195418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.